Enhanced recovery pathway is compromised by increased wound oozing due to chemical thromboprophylaxis increasing length of stay (LoS) and complications. We aimed to analyse the difference between LoS, VTE episodes, deep infection and return to theatre between matched cohort of patients either receiving combination therapy of Clexane followed by Rivaroxaban or Rivaroxaban only. We retrospectively collected data on LoS of patients undergoing hip and knee replacements, The cohorts consisted of 458 THRs (235 group I & 223 group II and 526 TKRs (250 group I & 276 group II). Group I received Rivaroxaban. Age was not an exclusion criteria and matched in both groups. ASA 1 to stable ASA3 patients were included in the cohort. Included were patients on aspirin 75 mg PO which was not stopped pre-operatively in either cohort in equal numbers. Anaesthetic and perioperative management of the patients as part of our enhanced recovery protocols were the same for both groups. Multimodal pain management, antibiotic prophylaxis, same day mobilisation, flowtron calf pumps, TED stockings, preoperative MRSA screening was standardised and matched. For TKRs a standard medial parapatellar approach and THRs a standard posterolateral (Southern) approach were utilised. Patients did not have a drain insitu. Exclusion criteria was patients with malignancy, haematological co-morbidities, Hb below 11 and BMI greater than 40. All prosthesis used were standardised to cemented TKR, cemented THR or uncemented THR depending on bone quality at the time of surgery. Patients in first cohort (group I) received 10 mg Rivaroxaban at 8 hours post op and continued for 14 days for TKRs and 35 days for THRs. Patients in group II received Clexane 40 mg SC at 8 hours post op followed by Rivaroxaban at 24 hours after first dose of Clexane and continued daily for 14 days for TKRs and 35 days for THRs.Aim:
Methods:
